Abstract 17373: Prevalence and Predictors of Atrial Fibrillation Type Among Individuals With Recent Onset of Atrial Fibrillation
Introduction: Atrial fibrillation (AF) is considered to be a progressive disease starting with short intermittent episodes, which over time progress to more sustained arrhythmia events. However, little is known about the prevalence of and predictors for AF type among patients with recent-onset AF.
Hypothesis: Several individuals might present a persistent form of AF shortly after the diagnosis. Different predictors for the rapid progression and the slow progression of AF might be present.
Methods: The Basel atrial fibrillation cohort (BEAT-AF) study is an ongoing prospective multicenter cohort study among patients with confirmed AF. At baseline, we obtained information on date of AF diagnosis, AF type, comorbidities, medication and lifestyle factors. For this analysis, 487 (31.4%) out of 1551 BEAT-AF participants with AF duration <24 months were included. Predictors for AF type (paroxysmal vs. non-paroxysmal) where obtained using multivariable adjusted logistic regression models.
Results: Mean age of the study population was 66 years and 136 (28%) were women. Recent-onset paroxysmal AF was observed in 302 (62%) participants, 185 (38%) had non-paroxysmal AF (persistent AF among 148 (30.4%), permanent AF among 37 (7.6%)). In multivariable models, odd ratios (OR) (95% confidence intervals (CI)) for the presence of paroxysmal AF at baseline were 0.98 (0.96-0.998), p=0.04 for age; 0.35 (0.20-0.62), p=0.0003 for history of heart failure (HF); 0.23 (0.07-0.80), p=0.02 for history of hyperthyroidism; 1.62 (1.19-2.21), p=0.002 for Sokolow-Lyon-Index and 0.97 (0.96-0.98), p<0.0001 for hear rate. Predictive values of all analyzed variables are shown in the table.
Conclusion: Among 487 individuals with recent-onset AF, 185 (38%) presented with non-paroxysmal AF. Predictors for non-paroxysmal AF were increasing age, history of heart failure or hyperthyroidism, a higher heart rate and a reduced Sokolow-Lyon index.
Author Disclosures: F. Ruperti-Repilado: None. L. Doerig: None. S. Blum: None. S. Aeschbacher: None. P. Krisai: None. P. Ammann: None. P. Erne: None. G. Moschovitis: None. M. di Valentino: None. D. Shah: Honoraria; Modest; For participating in NOAC related meetings for Edoxaban and Apixaban. J. Schläpfer: Research Grant; Modest; relationships with Daiichi Sankyo, Bayer & Boehringer-Ingelheim. S. Stempfel: None. M. Kühne: Research Grant; Modest; rom Sanofi Aventis, Bayer and Boehringer Ingelheim.. Speakers Bureau; Modest; for Boston Scientific, St. Jude Medical and Biotronik.. Honoraria; Modest; from Sorin, Boehringer Ingelheim, Bayer, Sanofi Aventis, Novartis and MSD. Consultant/Advisory Board; Modest; proctor for Medtronic. C. Sticherling: None. S. Osswald: None. D. Conen: Research Grant; Significant; Swiss National Science Foundation, the Swiss Heart Foundation, the University of Basel, Boehringer Ingelheim, Sanofi-Aventis, Merck Sharp & Dome, Bayer, Daiichi-Sankyo and Pfizer/Bristol-Myers Squibb..
- © 2016 by American Heart Association, Inc.